보고서 요약(국문)

개요
전 세계 로사이-도르프만병 시장은 2022년 4억 500만 달러에 달했으며, 2023년부터 2030년까지 연평균 6.6%의 성장률을 보이며 2030년에는 6억 6,750만 달러에 이를 것으로 예상됩니다.
로사이-도르프만병(RDD)은 조직구라고 불리는 백혈구의 과증식을 특징으로 하는 드물고 양성인 질환입니다. 일반적으로 목의 림프절이 붓는 증상을 나타내지만, 피부나 다른 장기에도 영향을 미칠 수 있습니다. 증상, 치료 옵션 및 예후는 개인마다 다릅니다.
로사이-도르프만병 환자의 대부분은 어린이, 청소년 및 젊은 성인입니다. RDD의 평균 발병 연령은 약 20세이지만, 70대 성인에게서도 RDD가 발생한 사례가 보고되었습니다. 아프리카계 남성에게서 림프절에 영향을 미치는 RDD가 가장 흔하게 발생합니다. 아시아계 사람들 중 출생 시 여성으로 지정된 사람들에게서 피부형 로사이-도르프만병(CRDD) 진단이 가장 흔하게 나타납니다. CRDD 환자는 대부분 20대, 30대, 40대입니다.
RDD는 여러 가지 원인이 있을 수 있으며, 각 환자에게서 다르게 나타납니다. 예를 들어, 최근 연구에 따르면 CRDD는 기존 RDD와는 다른 병인을 가질 가능성이 높습니다. 로사이-도르프만병은 유전자 변이를 보이는 유일한 림프절 외형 RDD 유형이 아닙니다. 유전자 돌연변이로 인해 세포의 성장이 통제되지 않을 수 있습니다.
변화 양상
FDA 승인 증가
독특한 조직학적 및 임상적 특성으로 인해 RDD는 연구자와 의료 전문가의 관심을 불러일으킨 흥미로운 질환입니다. RDD를 이해하면 연구자들은 건강과 질병 상태에서 면역계와 림프계가 어떻게 기능하는지 더 잘 이해할 수 있습니다. RDD 임상 시험 건수가 증가했을 가능성이 있습니다. 이러한 시험은 새로운 치료법을 평가하는 데 매우 중요하며, 긍정적인 결과가 나오면 FDA는 특정 약물이나 치료법을 승인할 수 있습니다. 예를 들어, 2023년 1월 30일, 미국 식품의약국(FDA)은 에르트하임-체스터병, 로사이-도르프만병, 랑게르한스 세포 조직구증과 같은 조직구 신생물을 앓는 성인 환자 치료를 위해 코비메티닙(코텔릭)을 승인했습니다. 이러한 규제 결정은 제넨텍과 메모리얼 슬론 케터링(MSK) 암센터의 협력으로 얻은 정보를 바탕으로 이루어졌습니다.
단일 기관, 단일군 임상시험 데이터에 따르면, 코비메티닙은 평균 11.4개월의 추적 관찰 기간 동안 모집된 26명의 환자에서 PET 검사 기준 76.9%, RECIST 기준 46.2%의 객관적 반응률(ORR)을 나타냈습니다. 코비메티닙의 승인은 수년간에 걸친 MSK 연구진들의 헌신적인 연구의 결실입니다. MSK에서 수행된 연구 및 임상시험 덕분에 희귀 악성 종양 분야에서 엄청난 발전이 이루어졌습니다. 따라서 위의 요인들은 시장 성장을 촉진하는 데 도움이 됩니다.
로사이-도르프만병에 대한 인식 제고
로사이-도르프만병(RDD)에 대한 인식이 높아짐에 따라 치료법 개발이 진행되고 있습니다. RDD는 진단과 치료가 어려운 희귀 질환으로, 의료 전문가와 일반인 모두 질환에 대한 이해가 부족한 경우가 많습니다. 그러나 RDD에 대한 정보가 더 많이 제공됨에 따라 조기 진단과 적절한 치료의 중요성에 대한 인식이 높아지고 있습니다.
환자 지원 네트워크와 옹호 단체를 통해 RDD는 더욱 널리 알려지고 있습니다. 이러한 단체들은 RDD에 대한 이해를 높이고 환자와 가족에게 정보와 지원을 제공하기 위해 노력합니다. 또한 지식과 개인적인 경험을 공유함으로써 대중과 전문가의 RDD 인식 제고에 기여합니다.
RDD에 대한 인식을 높이는 또 다른 중요한 방법은 의학 컨퍼런스와 교육 프로그램을 활용하는 것입니다. 이러한 행사는 학자, 의사, 기업 임원들이 최신 연구 결과와 치료법을 교환할 수 있는 기회를 제공합니다. 이러한 행사는 RDD에 대한 인식과 이해를 높여 RDD 환자 치료의 질을 향상시키는 데 도움이 됩니다. 따라서 위의 요인들은 시장 성장을 가속화하는 데 도움이 됩니다.
로사이-도르프만병의 제한적인 치료 옵션
더 흔한 질환에 비해 로사이-도르프만병은 희귀 질환이므로 연구 대상 환자 수가 적고 연구 자원도 부족합니다. 유병률이 낮아 광범위한 임상 연구를 수행하고 맞춤형 치료법을 개발하기 어렵습니다. 로사이-도르프만병의 정확한 원인과 기저 메커니즘은 아직 완전히 밝혀지지 않았습니다. 이러한 지식 부족으로 인해 맞춤형 치료제 개발이 저해되고 있습니다.
면역 세포 유형인 조직구가 로사이-도르프만병에서 과다 생성되지만, 이러한 과다 생성의 원인은 불분명합니다. 로사이-도르프만병은 이질적인 질환으로, 사람마다 다르게 나타날 수 있습니다. 어떤 사람은 경미하거나 저절로 낫는 증상을 보이는 반면, 다른 사람은 더 심각한 증상이나 문제를 겪을 수 있습니다. 따라서 로사이-도르프만병의 제한적인 치료 옵션은 시장 확장을 저해할 수 있습니다.
보고서에 대한 자세한 내용은 샘플을 요청하십시오.
세분화 분석
글로벌 로사이-도르프만병 시장은 유형, 연령대, 시술 유형, 최종 사용자 및 지역별로 세분화됩니다.

로자이-도르프만병(RDD) 치료에서 화학요법은 중요한 역할을 합니다.
화학요법은 일반적으로 로자이-도르프만병의 1차 치료법은 아닙니다. RDD는 림프절 및 기타 조직에 조직구(면역 세포의 일종)가 과다 생성 및 축적되는 희귀 질환입니다. RDD 치료법은 질병의 중증도, 발생 부위 및 유발하는 증상에 따라 결정됩니다.
RDD의 주요 치료법은 일반적으로 경과 관찰이며, 특히 질병이 경미하고 심각한 증상이나 장기 기능 장애를 유발하지 않는 경우에 그렇습니다. 이러한 경우 자연적으로 퇴행하거나 질병이 진행되지 않는 경우가 흔하며, 치료가 필요하지 않을 수 있습니다. 그러나 RDD가 장기 기능 장애, 통증 또는 주요 구조물 압박과 같은 심각한 증상을 유발하는 경우 치료가 필요할 수 있습니다.
또한, RDD가 광범위하거나 전신적으로 침범한 경우, 특히 다른 치료법이 효과가 없거나 빠른 진행이 관찰될 때 화학요법을 고려할 수 있습니다. 코르티코스테로이드, 빈카 알칼로이드, 면역 조절제 등 다양한 화학 요법이 사용되어 왔습니다.
지리적 시장 침투
북미 지역의 임상 시험 및 제품 출시 증가
북미는 인구 규모, 우수한 의료 인프라, 높은 소득 수준으로 인해 전 세계 로사이-도르프만병 시장을 주도하고 있습니다. 전 세계 로사이-도르프만병 시장은 여러 미시경제 및 거시경제 변수에 기반합니다. 암, 바이러스 감염 등 혈액 관련 질환의 유병률 증가가 시장 확장에 기여하고 있습니다.
신속한 진단에 대한 수요 증가로 인해 이 지역의 기업들은 더욱 정교한 방법 개발에 집중하고 있습니다. 아직 승인을 받지 않은 임상 시험의 증가가 시장 확장을 가속화할 것으로 예상됩니다. 의사, 환자, 옹호 단체 및 연구자들의 활동으로 혈액 관련 질환에 대한 소비자 인식이 높아짐에 따라 임상 시험 참여자가 늘어나면서 제약 회사들은 이익을 얻을 것으로 예상됩니다.
예측 기간 동안 아시아 태평양 지역이 가장 빠른 성장을 보일 것으로 예상됩니다. 희귀질환 환자들을 돕기 위한 정부 프로그램들이 이 지역의 질병 확산에 대한 원인으로 지목되고 있습니다.
코로나19 영향 분석
많은 지역의 의료 시스템은 코로나19 유행 기간 동안 자원 부족과 정기적인 의료 서비스 중단 등 심각한 어려움을 겪었습니다. 이로 인해 희귀질환 환자의 상태 모니터링 및 치료를 포함한 의료 서비스 접근성이 영향을 받았을 수 있습니다. 또한, 여러 의료 전문 분야에서 임상 시험 및 연구가 유행으로 인해 차질을 빚었습니다. 팬데믹은 희귀질환 연구를 지연시키거나 손상시켜 질병에 대한 이해와 치료를 늦췄을 가능성이 있습니다.

유형별
• 고전적(결절성) 로사이-도르프만병
• 결절외 로사이-도르프만병
연령대별
• 소아
• 성인
시술 유형별
• 진단
o 영상 검사
 MRI
 CT 스캔
 핵의학
o 혈액 검사
o 생검
• 치료
o 수술
o 방사선 치료
o 화학 요법
o 코르티코스테로이드
o 면역 요법
최종 사용자별
• 병원
• 진단 센터
• 암 센터
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 이탈리아
o 스페인
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
주요 동향
• 2022년 11월 28일, 한 도시의 사립 병원에서 한 환자가 로사이-도르프만병(RDD)은 심장에 영향을 미치는 희귀 면역 질환으로, 효과적으로 치료되었습니다. 눈과 심장에 영향을 미치는 이 질환은 전 세계적으로 현재까지 단 8건만 보고되었습니다.
경쟁 환경
주요 글로벌 시장 참여 기업으로는 Koninklijke Philips N.V., GE HealthCare, Canon Inc, Siemens Healthineers, SternMed GmbH, Jubilant Cadista Pharmaceuticals Inc, LGM Pharma, Henan Lihua Pharmaceutical Co., Ltd, Niksan Pharmaceutical, Sandoz Canada Inc 등이 있습니다.
보고서 구매 이유

• 유형, 연령대, 시술 유형, 최종 사용자 및 지역별 글로벌 로사이-도르프만병 시장 세분화를 시각화하고 주요 상업 자산 및 기업을 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 모색합니다.

• 모든 세그먼트를 포함한 로사이-도르프만병 시장 수준의 다양한 데이터가 담긴 Excel 데이터 시트를 제공합니다.

• PDF 보고서는 철저한 질적 인터뷰와 심층 연구를 바탕으로 한 종합적인 분석 자료로 구성되어 있습니다.

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 자료는 엑셀 파일로 제공됩니다.
글로벌 로사이-도르프만병 시장 보고서는 약 61개의 표, 58개의 그림, 186페이지 분량입니다.
주요 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Rosai-Dorfman Disease Market reached US$ 405.0 million in 2022 and is expected to reach US$ 667.5 million by 2030, growing with a CAGR of 6.6% during the forecast period 2023-2030.
Rosai-Dorfman disease (RDD) is a rare, benign condition that involves an overgrowth of white blood cells called histiocytes. It usually causes swollen lymph glands in the neck, but overgrowths can also affect to skin and other organs. Symptoms, treatment options and likely outcomes vary from person to person.
Most people with Rosai-Dorfman disease are children, teenagers, and young adults. The average age of Procedure Type for RDD is around 20, but incidences of RDD involving adults in their 70s have been documented. People of African origin who are born male most typically get RDD that affects the lymph nodes. People of Asian heritage who are assigned to the female gender at birth are most commonly diagnosed with cutaneous RDD. Most CRDD sufferers are in their 20s, 30s, and 40s.
RDD may have several reasons because each person is affected by it differently. For instance, current research indicates that CRDD is likely to have distinct aetiology from traditional RDD. Rosai-Dorfman disease is not the only extranodal RDD type that occasionally exhibit gene alterations, according to current research. A cell's growth might become uncontrolled due to gene mutations.
Dynamics
The Rise of FDA Approvals
Due to its unique histology and clinical characteristics, RDD is an interesting disease that has sparked the interest of researchers and medical professionals. Understanding RDD can help researchers better understand how the immune and lymphatic systems function in both health and sickness. The number of RDD clinical trials may have increased. These trials are crucial for evaluating novel therapies, and if any of them yield positive findings, the FDA might approve specific drugs or therapies.
For instance, January 30, 2023, For the treatment of adult patients with histiocytic neoplasms like Erdheim-Chester disease, Rosai-Dorfman disease, and Langerhans cell histiocytosis, the FDA has approved cobimetinib (Cotellic). The regulatory choice was supported by information gathered as a result of a partnership between Genentech and Memorial Sloan Kettering (MSK) Cancer Centre.
According to data from the single-center, one-arm trial, cobimetinib produced an objective response rate (ORR) of 76.9% by PET and 46.2% by RECIST criteria in 26 recruited patients at a median follow-up of 11.4 months. The diligent work of several MSK researchers over the course of several years of research culminated in the approval of cobimetinib. As a result of the research and clinical trials carried out at MSK, there have been enormous advancements in the field of uncommon malignancies. Thus above factors helps to boost the market growth.
Raising Awareness of Rosai-Dorfman Disease
Rosai-Dorfman Disease treatment options are being developed as a result of rising Rosai-Dorfman Disease awareness. RDD is a rare disease that can be difficult to detect and treat, and both healthcare professionals and the general population sometimes have little understanding of the condition. However, there is rising understanding of the significance of early diagnosis and proper treatment as more information regarding RDD becomes accessible.
Through patient support networks and advocacy groups, RDD is becoming more widely known. These groups look for to increase understanding of RDD and offer information and support to patients and their families. These groups aid in raising public and professional awareness of RDD by sharing knowledge and personal experiences.
An additional significant method for raising awareness of RDD is through medical conferences and educational initiatives. These events give scholars, doctors, and executives from businesses the chance to exchange the most recent research findings and treatments. These occasions assist to raise awareness and understanding of RDD, which enhances the standard of care for patients with RDD. Thus above factors helps to accelerate the market growth.
Limited Treatment Options for the Rosai-Dorfman Disease
Compared to more widespread disorders, RDD is a rare disease, thus there are fewer patients to study and fewer resources available for research. It is difficult to conduct extensive clinical studies and create tailored treatments because of the low prevalence. RDD's precise cause and underlying mechanisms are not completely understood. The development of focused medicines is hampered by this lack of knowledge.
Histiocytes, an immunological cell type, are produced excessively in RDD, however it is unclear what causes this excessive production. RDD is a heterogeneous condition, which means that it can manifest differently in various people. While some people have mild or self-limiting illnesses, others might have more serious signs or problems. Thus, the market's expansion will be hindered by the limited treatment options for the RDD.
For more details of the report, Request for sample
Segment Analysis
The global rosai-dorfman disease market is segmented based on type, age group, procedure type, end user and region.
Chemotherapy Play a Critical Part in the Treatment of RDD
Chemotherapy is not typically the first-line treatment for rosai-dorfman disease. RDD is a rare disorder characterized by the overproduction and accumulation of histiocytes (a type of immune cell) in lymph nodes and other tissues. The choice of treatment for RDD depends on the severity of the disease, its location, and the symptoms it causes.
The primary treatment for RDD usually involves a watch-and-wait approach, especially for cases where the disease is mild and not causing significant symptoms or organ dysfunction. In such cases, spontaneous regression or no progression of the disease is common, and treatment may not be necessary. However, if RDD is causing severe symptoms, such as organ dysfunction, pain, or compression of vital structures, treatment may be required.
Additionally, chemotherapy may be considered in cases of RDD with widespread or systemic involvement, particularly when other treatments have failed or when rapid progression is observed. Various chemotherapy regimens have been used, including corticosteroids, vinca alkaloids, and immune-modulating agents.
Geographical Penetration
Rising Clinical Trails and Product Launches in the North American Region
North America dominates the global rosai-dorfman disease market primarily due to its large population, excellent medical infrastructure, and high-income levels. The global rosai-dorfman disease is based on a number of micro- and macroeconomic variables. The prevalence of diseases associated with blood like cancer and viral infections contributes to the market's expansion.
Increased need for faster diagnosis led companies in the region to concentrate on more sophisticated methods. It is expected that an increase in clinical trials that have not yet received approval will accelerate market expansion. It is anticipated that the drug manufacturers will benefit as more individuals sign up for clinical trials as a result of increased consumer knowledge of blood-related diseases among consumers brought on by doctors, patients, advocacy groups, and researchers.
Throughout the projected period, the Asia Pacific is expected to witness fastest growth. Government programmes aimed at helping people with orphan diseases are to blame for the region's expansion.
COVID-19 Impact Analysis
Healthcare systems in numerous regions noticed serious difficulties during the COVID-19 epidemic, including resource shortages and disruptions in regular medical treatment. Access to healthcare services, including monitoring and treatment of RDD patients' conditions, may have been impacted by this. Clinical trials and research have been hampered by the epidemic in many different medical specialties. The pandemic may have slowed down or damaged RDD research, which could have slowed down the understanding and treatment of the condition.
By Type
• Classic (nodal) Rosai-Dorfman disease
• Extranodal Rosai-Dorfman disease
By Age Group
• Children
• Adults
By Procedure Type
• Diagnosis
o Imaging procedures
 MRI
 CT scan
 Nuclear medicine
o Blood tests
o Biopsy
• Treatment
o Surgery
o Radiation therapy
o Chemotherapy
o Corticosteroids
o Immunotherapy
By End User
• Hospitals
• Diagnostic centers
• Cancer centers
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• On November 28, 2022, at a city private hospital, a patient with Rosai-Dorfman disease (RDD), a rare immunological condition that had compromised his heart, was effectively treated. Only eight cases of the illness that affects the eyes and the heart have been reported so far in the entire world.
Competitive Landscape
The major global players in the market include Koninklijke Philips N.V., GE HealthCare, Canon Inc, Siemens Healthineers, SternMed GmbH, Jubilant Cadista Pharmaceuticals Inc, LGM Pharma, Henan Lihua Pharmaceutical Co., Ltd, Niksan Pharmaceutical, Sandoz Canada Inc and among others.
Why Purchase the Report?
• To visualize the global rosai-dorfman disease market segmentation based on type, age group, procedure type, end user and region as well as understandkey commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of rosai-dorfman disease market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global Rosai-Dorfman Disease market report would provide approximately 61tables, 58figures and 186 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Age Group
3.3. Snippet by Procedure Type
3.4. Snippet by End User
3.5. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. The rise of FDA Approvals
4.1.1.2. Raising awareness of Rosai-Dorfman Disease
4.2. Restraints
4.2.1.1. Limited Treatment Options for the Rosai-Dorfman Disease
4.2.2. Opportunity
4.2.3. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type
7.2. Classic (nodal) Rosai-Dorfman disease*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Extranodal Rosai-Dorfman disease
8. By Age Group
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), ByAge Group
8.1.2. Market Attractiveness Index, By Age Group
8.2. Children*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Adults
9. By Procedure Type
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure Type
9.1.2. Market Attractiveness Index, By Procedure Type
9.2. *Diagnosis
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.2.3. Imaging procedures
9.2.3.1. MRI
9.2.3.2. CT scan
9.2.3.3. Nuclear medicine
9.2.4. Blood tests
9.2.5. Biopsy
9.2.6. Surgery
9.3. Treatment
9.3.1. Radiation therapy
9.3.2. Chemotherapy
9.3.3. Corticosteroids
9.3.4. Immunotherapy
10. By End User
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
10.1.2. Market Attractiveness Index, By End User
10.2. Hospitals*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Diagnostic centers
10.4. Cancer centers
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure Type
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure Type
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. UK
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Spain
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure Type
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure Type
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedure Type
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Koninklijke Philips N.V.*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. GE HealthCare
13.3. Canon Inc
13.4. Siemens Healthineers
13.5. SternMed GmbH
13.6. Jubilant Cadista Pharmaceuticals Inc
13.7. LGM Pharma
13.8. Henan Lihua Pharmaceutical Co., Ltd
13.9. Niksan Pharmaceutical
13.10. Sandoz Canada Inc
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us

언급된 주요 기업들

Koninklijke Philips N.V., 4.	Key Developments, GE HealthCare, Canon Inc, Siemens Healthineers, SternMed GmbH, Jubilant Cadista Pharmaceuticals Inc, LGM Pharma, Henan Lihua Pharmaceutical Co., Ltd, Niksan Pharmaceutical, Sandoz Canada Inc

표 목록 (Tables)

List of Tables

Table 1 Global Rosai-Dorfman Disease Market Value, By Type, 2022, 2026 & 2030 (US$ Billion)

Table 2 Global Rosai-Dorfman Disease Market Value, By Age Group, 2022, 2026 & 2030 (US$ Billion)

Table 3 Global Rosai-Dorfman Disease Market Value, By Procedure Type, 2022, 2026 & 2030 (US$ Billion)

Table 4 Global Rosai-Dorfman Disease Market Value, By End User, 2022, 2026 & 2030 (US$ Billion)

Table 5 Global Rosai-Dorfman Disease Market Value, By Region, 2022, 2026 & 2030 (US$ Billion)

Table 6 Global Rosai-Dorfman Disease Market Value, By Type, 2022, 2026 & 2030 (US$ Billion)

Table 7 Global Rosai-Dorfman Disease Market Value, By Type, 2021-2030 (US$ Billion)

Table 8 Global Rosai-Dorfman Disease Market Value, By Age Group, 2022, 2026 & 2030 (US$ Billion)

Table 9 Global Rosai-Dorfman Disease Market Value, By Age Group, 2021-2030 (US$ Billion)

Table 10 Global Rosai-Dorfman Disease Market Value, By Procedure Type, 2022, 2026 & 2030 (US$ Billion)

Table 11 Global Rosai-Dorfman Disease Market Value, By Procedure Type, 2021-2030 (US$ Billion)

Table 12 Global Rosai-Dorfman Disease Market Value, By End User, 2022, 2026 & 2030 (US$ Billion)

Table 13 Global Rosai-Dorfman Disease Market Value, By End User, 2021-2030 (US$ Billion)

Table 14 Global Rosai-Dorfman Disease Market Value, By Region, 2022, 2026 & 2030 (US$ Billion)

Table 15 Global Rosai-Dorfman Disease Market Value, By Region, 2021-2030 (US$ Billion)

Table 16 North America Rosai-Dorfman Disease Market Value, By Type, 2021-2030 (US$ Billion)

Table 17 North America Rosai-Dorfman Disease Market Value, By Age Group, 2021-2030 (US$ Billion)

Table 18 North America Rosai-Dorfman Disease Market Value, By Procedure Type, 2021-2030 (US$ Billion)

Table 19 North America Rosai-Dorfman Disease Market Value, By End User, 2021-2030 (US$ Billion)

Table 20 North America Rosai-Dorfman Disease Market Value, By Country, 2021-2030 (US$ Billion)

Table 21 South America Rosai-Dorfman Disease Market Value, By Type, 2021-2030 (US$ Billion)

Table 22 South America Rosai-Dorfman Disease Market Value, By Age Group, 2021-2030 (US$ Billion)

Table 23 South America Rosai-Dorfman Disease Market Value, By Procedure Type, 2021-2030 (US$ Billion)

Table 24 South America Rosai-Dorfman Disease Market Value, By End User, 2021-2030 (US$ Billion)

Table 25 South America Rosai-Dorfman Disease Market Value, By Country, 2021-2030 (US$ Billion)

Table 26 Europe Rosai-Dorfman Disease Market Value, By Type, 2021-2030 (US$ Billion)

Table 27 Europe Rosai-Dorfman Disease Market Value, By Age Group, 2021-2030 (US$ Billion)

Table 28 Europe Rosai-Dorfman Disease Market Value, By Procedure Type, 2021-2030 (US$ Billion)

Table 29 Europe Rosai-Dorfman Disease Market Value, By End User, 2021-2030 (US$ Billion)

Table 30 Europe Rosai-Dorfman Disease Market Value, By Country, 2021-2030 (US$ Billion)

Table 31 Asia-Pacific Rosai-Dorfman Disease Market Value, By Type, 2021-2030 (US$ Billion)

Table 32 Asia-Pacific Rosai-Dorfman Disease Market Value, By Age Group, 2021-2030 (US$ Billion)

Table 33 Asia-Pacific Rosai-Dorfman Disease Market Value, By Procedure Type, 2021-2030 (US$ Billion)

Table 34 Asia-Pacific Rosai-Dorfman Disease Market Value, By End User, 2021-2030 (US$ Billion)

Table 35 Asia-Pacific Rosai-Dorfman Disease Market Value, By Country, 2021-2030 (US$ Billion)

Table 36 Middle East & Africa Rosai-Dorfman Disease Market Value, By Type, 2021-2030 (US$ Billion)

Table 37 Middle East & Africa Rosai-Dorfman Disease Market Value, By Age Group, 2021-2030 (US$ Billion)

Table 38 Middle East & Africa Rosai-Dorfman Disease Market Value, By Procedure Type, 2021-2030 (US$ Billion)

Table 39 Middle East & Africa Rosai-Dorfman Disease Market Value, By End User, 2021-2030 (US$ Billion)

Table 40 Koninklijke Philips N.V.: Overview

Table 41 Koninklijke Philips N.V.: Product Portfolio

Table 42 Koninklijke Philips N.V.: Key Developments

Table 43 GE HealthCare: Overview

Table 44 GE HealthCare: Product Portfolio

Table 45 GE HealthCare: Key Developments

Table 46 Canon Inc: Overview

Table 47 Canon Inc: Product Portfolio

Table 48 Canon Inc: Key Developments

Table 49 Siemens Healthineers: Overview

Table 50 Siemens Healthineers: Product Portfolio

Table 51 Siemens Healthineers: Key Developments

Table 52 SternMed GmbH: Overview

Table 53 SternMed GmbH: Product Portfolio

Table 54 SternMed GmbH: Key Developments

Table 55 Jubilant Cadista Pharmaceuticals Inc: Overview

Table 56 Jubilant Cadista Pharmaceuticals Inc: Product Portfolio

Table 57 Jubilant Cadista Pharmaceuticals Inc: Key Developments

Table 58 LGM Pharma: Overview

Table 59 LGM Pharma: Product Portfolio

Table 60 LGM Pharma: Key Developments

Table 61 Henan Lihua Pharmaceutical Co., Ltd: Overview

Table 62 Henan Lihua Pharmaceutical Co., Ltd: Product Portfolio

Table 63 Henan Lihua Pharmaceutical Co., Ltd: Key Developments

Table 64 Niksan Pharmaceutical: Overview

Table 65 Niksan Pharmaceutical: Product Portfolio

Table 66 Niksan Pharmaceutical: Key Developments

Table 67 Sandoz Canada Inc: Overview

Table 68 Sandoz Canada Inc: Product Portfolio

Table 69 Sandoz Canada Inc: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Rosai-Dorfman Disease Market Value, 2021-2030 (US$ Billion)

Figure 2 Global Rosai-Dorfman Disease Market Share, By Type, 2022 & 2030 (%)

Figure 3 Global Rosai-Dorfman Disease Market Share, By Age Group, 2022 & 2030 (%)

Figure 4 Global Rosai-Dorfman Disease Market Share, By Procedure Type, 2022 & 2030 (%)

Figure 5 Global Rosai-Dorfman Disease Market Share, By End User, 2022 & 2030 (%)

Figure 6 Global Rosai-Dorfman Disease Market Share, By Region, 2022 & 2030 (%)

Figure 7 Global Rosai-Dorfman Disease Market Y-o-Y Growth, By Type, 2022-2030 (%)

Figure 8 Classic (nodal) Rosai-Dorfman disease Rosai-Dorfman Disease Market Value, 2021-2030 (US$ Billion)

Figure 9 Extranodal Rosai-Dorfman disease Rosai-Dorfman Disease Market Value, 2021-2030 (US$ Billion)

Figure 10 Global Rosai-Dorfman Disease Market Y-o-Y Growth, By Age Group, 2022-2030 (%)

Figure 11 Children Age Group in Global Rosai-Dorfman Disease Market Value, 2021-2030 (US$ Billion)

Figure 12 Adults Age Group in Global Rosai-Dorfman Disease Market Value, 2021-2030 (US$ Billion)

Figure 13 Global Rosai-Dorfman Disease Market Y-o-Y Growth, By Procedure Type, 2022-2030 (%)

Figure 14 Imaging procedures Procedure Type in Global Rosai-Dorfman Disease Market Value, 2021-2030 (US$ Billion)

Figure 15 Treatment Procedure Type in Global Rosai-Dorfman Disease Market Value, 2021-2030 (US$ Billion)

Figure 16 Global Rosai-Dorfman Disease Market Y-o-Y Growth, By End User, 2022-2030 (%)

Figure 17 Hospitals End User in Global Rosai-Dorfman Disease Market Value, 2021-2030 (US$ Billion)

Figure 18 Diagnostic centers End User in Global Rosai-Dorfman Disease Market Value, 2021-2030 (US$ Billion)

Figure 19 Cancer centers End User in Global Rosai-Dorfman Disease Market Value, 2021-2030 (US$ Billion)

Figure 20 Global Rosai-Dorfman Disease Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 21 North America Rosai-Dorfman Disease Market Value, 2021-2030 (US$ Billion)

Figure 22 Asia-Pacific Rosai-Dorfman Disease Market Value, 2021-2030 (US$ Billion)

Figure 23 Europe Rosai-Dorfman Disease Market Value, 2021-2030 (US$ Billion)

Figure 24 South America Rosai-Dorfman Disease Market Value, 2021-2030 (US$ Billion)

Figure 25 Middle East and Africa Rosai-Dorfman Disease Market Value, 2021-2030 (US$ Billion)

Figure 26 North America Rosai-Dorfman Disease Market Value, 2021-2030 (US$ Billion)

Figure 27 North America Rosai-Dorfman Disease Market Share, By Type, 2022 & 2030 (%)

Figure 28 North America Rosai-Dorfman Disease Market Share, By Age Group, 2022 & 2030 (%)

Figure 29 North America Rosai-Dorfman Disease Market Share, By Procedure Type, 2022 & 2030 (%)

Figure 30 North America Rosai-Dorfman Disease Market Share, By End User, 2022 & 2030 (%)

Figure 31 North America Rosai-Dorfman Disease Market Share, By Country, 2022 & 2030 (%)

Figure 32 South America Rosai-Dorfman Disease Market Value, 2021-2030 (US$ Billion)

Figure 33 South America Rosai-Dorfman Disease Market Share, By Type, 2022 & 2030 (%)

Figure 34 South America Rosai-Dorfman Disease Market Share, By Age Group, 2022 & 2030 (%)

Figure 35 South America Rosai-Dorfman Disease Market Share, By Procedure Type, 2022 & 2030 (%)

Figure 36 South America Rosai-Dorfman Disease Market Share, By End User, 2022 & 2030 (%)

Figure 37 South America Rosai-Dorfman Disease Market Share, By Country, 2022 & 2030 (%)

Figure 38 Europe Rosai-Dorfman Disease Market Value, 2021-2030 (US$ Billion)

Figure 39 Europe Rosai-Dorfman Disease Market Share, By Type, 2022 & 2030 (%)

Figure 40 Europe Rosai-Dorfman Disease Market Share, By Age Group, 2022 & 2030 (%)

Figure 41 Europe Rosai-Dorfman Disease Market Share, By Procedure Type, 2022 & 2030 (%)

Figure 42 Europe Rosai-Dorfman Disease Market Share, By End User, 2022 & 2030 (%)

Figure 43 Europe Rosai-Dorfman Disease Market Share, By Country, 2022 & 2030 (%)

Figure 44 Asia-Pacific Rosai-Dorfman Disease Market Value, 2021-2030 (US$ Billion)

Figure 45 Asia-Pacific Rosai-Dorfman Disease Market Share, By Type, 2022 & 2030 (%)

Figure 46 Asia-Pacific Rosai-Dorfman Disease Market Share, By Age Group, 2022 & 2030 (%)

Figure 47 Asia-Pacific Rosai-Dorfman Disease Market Share, By Procedure Type, 2022 & 2030 (%)

Figure 48 Asia-Pacific Rosai-Dorfman Disease Market Share, By End User, 2022 & 2030 (%)

Figure 49 Asia-Pacific Rosai-Dorfman Disease Market Share, By Country, 2022 & 2030 (%)

Figure 50 Middle East & Africa Rosai-Dorfman Disease Market Value, 2021-2030 (US$ Billion)

Figure 51 Middle East & Africa Rosai-Dorfman Disease Market Share, By Type, 2022 & 2030 (%)

Figure 52 Middle East & Africa Rosai-Dorfman Disease Market Share, By Age Group, 2022 & 2030 (%)

Figure 53 Middle East & Africa Rosai-Dorfman Disease Market Share, By Procedure Type, 2022 & 2030 (%)

Figure 54 Middle East & Africa Rosai-Dorfman Disease Market Share, By End User, 2022 & 2030 (%)

Figure 55 Koninklijke Philips N.V.: Financials

Figure 56 GE HealthCare: Financials

Figure 57 Canon Inc: Financials

Figure 58 Siemens Healthineers: Financials

Figure 59 SternMed GmbH: Financials

Figure 60 Jubilant Cadista Pharmaceuticals Inc: Financials

Figure 61 LGM Pharma: Financials

Figure 62 Henan Lihua Pharmaceutical Co., Ltd: Financials

Figure 63 Niksan Pharmaceutical: Financials

Figure 64 Sandoz Canada Inc: Financials

글로벌 로사이-도르프만병 시장 – 2023-2030

Global Rosai-Dorfman Disease Market - 2023-2030